TABLE 3.
Lipoxygenase pathway-derived lipid mediators from ω-3 and ω-6 PUFAs in human amniotic fluid in TLB with or without clinical chorioamnionitis
| Lipid | TLB | TCC-noMIAC | TCC-MIAC | P (TLB vs. TCC-noMIAC) | P (TLB vs. TCC-MIAC) | P (TCC-noMIAC vs. TCC-MIAC) |
| 9(S)-HOTrE (ω-3) | 3.63 (2.72–4.92) [32] | 0.82 (0.02–2.57) [6] | 2.48 (0.02–4.99) [8] | 5.32 × 10−4 | 0.18 | 0.22 |
| 13(S)-HOTrE (ω-3) | 5.95 (2.98–8.51) [34] | 2.47 (1.38–3.88) [9] | 4.07 (2.29–9.25) [12] | 2.28 × 10−3 | 0.75 | 0.13 |
| 5-HEPE (ω-3) | 0.02 (0.02–1.89) [16] | 0.02 (0.02–0.02) [1] | 0.02 (0.02–1.44) [5] | 0.02 | 0.56 | 0.06 |
| 11-HEPE (ω-3) | 2.01 (1.66–2.24) [30] | 2.67 (1.99–3.45) [12] | 2.50 (2.17–3.02) [12] | 0.02 | 0.01 | 0.67 |
| 12-HEPE (ω-3) | 10.9 (8.74–18.1) [35] | 4.11 (3.37–5.34) [11] | 9.53 (6.48–13.9) [12] | 1.99 × 10−6 | 0.25 | 2.32 × 10−3 |
| 15-HEPE (ω-3) | 1.50 (0.02–2.58) [23] | 0.02 (0.02–0.17) [3] | 2.18 (0.02–2.95) [8] | 0.01 | 0.73 | 0.02 |
| 4-HDoHE (ω-3) | 3.66 (1.79–6.65) [32] | 0.81 (0.02–2.51) [6] | 4.44 (2.56–5.70) [11] | 4.69 × 10−3 | 0.81 | 0.01 |
| 7-HDoHE (ω-3) | 3.37 (2.40–5.85) [33] | 0.02 (0.02–1.13) [4] | 1.93 (1.00–3.32) [10] | 1.35 × 10−5 | 0.05 | 0.01 |
| 10-HDoHE (ω-3) | 2.69 (1.51–4.06) [29] | 0.02 (0.02–1.58) [4] | 2.92 (2.37–4.18) [10] | 8.07 × 10−4 | 0.49 | 1.09 × 10−3 |
| 11-HDoHE (ω-3) | 9.70 (7.26–13.3) [35] | 2.98 (2.64–6.36) [11] | 11.0 (6.31–17.0) [12] | 3.18 × 10−5 | 0.97 | 1.11 × 10−3 |
| 13-HDoHE (ω-3) | 2.15 (1.24–3.46) [30] | 0.02 (0.02–0.93) [4] | 1.79 (0.79–3.45) [9] | 1.14 × 10−4 | 0.46 | 0.01 |
| 14-HDoHE (ω-3) | 19.2 (11.8–24.0) [35] | 6.81 (5.17–11.4) [12] | 14.9 (10.4–31.2) [12] | 4.93 × 10−4 | 0.80 | 0.02 |
| 17-HDoHE (ω-3) | 3.29 (1.67–5.79) [30] | 1.27 (0.02–2.51) [7] | 5.06 (2.72–8.04) [11] | 0.01 | 0.47 | 0.01 |
| 20-HDoHE (ω-3) | 1.61 (1.14–4.47) [27] | 0.02 (0.02–0.27) [3] | 1.82 (1.06–3.82) [10] | 3.35 × 10−4 | 0.92 | 1.77 × 10−3 |
| 13(S)-HOTrE (γ) (ω-6) | 10.6 (7.50–17.7) [35] | 5.57 (2.73–8.28) [12] | 7.88 (4.29–10.4) [12] | 1.03 × 10−3 | 0.07 | 0.27 |
| 8-HETrE (ω-6) | 16.8 (11.4–28.9) [35] | 7.00 (5.67–11.5) [12] | 17.1 (12.7–31.1) [12] | 1.55 × 10−4 | 0.76 | 0.01 |
| 8-HETE (ω-6) | 7.43 (4.66–11.9) [34] | 3.25 (2.62–4.46) [11] | 11.6 (6.27–16.6) [12] | 5.3 × 10−4 | 0.09 | 7.17 × 10−5 |
| 11-HETE (ω-6) | 19.2 (11.7–29.5) [35] | 10.9 (4.64–16.5) [12] | 28.9 (15.1–39.9) [12] | 0.009 | 0.25 | 0.005 |
| 12-HETE (ω-6) | 144.6 (108.7–207.1) [35] | 100.7 (69.2–137.8) [12] | 252.8 (163.7–373.4) [12] | 0.02 | 0.005 | 2.74 × 10−4 |
| 15-HETE (ω-6) | 21.8 (15.5–30.4) [35] | 14.7 (6.51–22.7) [12] | 54.6 (24.7–83.8) [12] | 0.09 | 0.03 | 0.003 |
HDoHE, hydroxy docosahexaenoic acid; HEDE, hydroxy eicosadienoic acid; HEPE, hydroxy eicosapentaenoic acid; HETrE, hydroxy eicosatrienoic acid; HOTrE, hydroxy octadecatrienoic acid. All concentrations are in nM. Values in parentheses are interquartile ranges of analyte concentrations in nM, and those in brackets are number of samples with detectable levels of the corresponding lipid mediators. All P values are derived from Wilcoxon tests. P values <0.05 are italicized.